Reaction
Differentiation Syndrome reporting signals
As of the last recalculation, Differentiation Syndrome appears in 706 FAERS reports alongside 22 co-occurring drug terms. The strongest observed disproportionality signal is TRETINOIN (PRR 1,222.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Tretinoin | 228 | 1,222.6 | 1,258.1 |
| Hydroxyurea | 100 | 162.3 | 163.0 |
| Posaconazole Delayed-Release | 53 | 153.7 | 154.5 |
| Posaconazole | 61 | 121.1 | 121.5 |
| Azacitidine For | 67 | 119.9 | 120.3 |
| Azacitidine | 89 | 101.0 | 101.4 |
| Cefepime Hydrochloride | 19 | 35.7 | 35.7 |
| Micafungin Sodium | 10 | 35.3 | 35.3 |
| Piperacillin Sodium,Tazobactam Sodium | 28 | 32.4 | 32.4 |
| Cefepime | 14 | 29.4 | 29.4 |
| Cytarabine | 53 | 28.0 | 28.1 |
| Piperacillin And Tazobactam | 10 | 23.4 | 23.4 |
| Linezolid | 22 | 22.5 | 22.5 |
| Febuxostat Tablets 40 Mg | 7 | 20.5 | 20.5 |
| Febuxostat Tablets 80 Mg | 7 | 20.5 | 20.5 |
| Voriconazole Injection | 14 | 19.4 | 19.4 |
| Meropenem | 20 | 18.9 | 18.9 |
| Venetoclax | 33 | 16.5 | 16.5 |
| Daptomycin | 5 | 16.1 | 16.1 |
| Febuxostat | 9 | 16.0 | 16.0 |
| Voriconazole | 16 | 15.9 | 15.9 |
| Oseltamivir | 3 | 11.2 | 11.2 |